When we reported the success of applying atorvastatin to treat chronic subdural hematoma (CSDH), many colleagues were asking what the mechanism was. 2014-2015, after 3 years of efforts and sacrificing a wave of our human friends (rats), we finally confirmed from molecular and cellular perspectives that inflammatory and angiogenic reactions occur during the formation and resorption of subdural hematoma, and atorvastatin can simultaneously Atorvastatin modulates both processes, accelerates hematoma resorption, and promotes neurological recovery in rats with subdural hematoma. Although the surgery is simple and the surgical recurrence rate is said to be low by some doctors (e.g., a doctor in Jiangsu Province believes that he operates on a group of about 100 cases per year and the recurrence rate is only less than 2%), most statistics show that the recurrence rate is close to 10%. The recurrence rate was 13.5% in a group of 126 cases of surgically treated CSDH, according to the recent statistics of the famous neurosurgeon Pan Weisheng in Hong Kong. It is estimated that the statistics of high and low surgical recurrence rates are related to the treating surgeon’s awareness of recurrence. 2015 statistics from a group of Europeans, Koreans and Japanese, their postoperative recurrence rates ranged from 18% to 29%. In any case, postoperative recurrence of CSDH objectively exists and patients would benefit from being cured without surgery. Our next step will be to improve the treatment based on this result. We will try to make the success rate of conservative treatment of CSDH higher. Let more people avoid the pain of surgery.